16 Fox Focus | Policy
As Parkinson’ s Costs Climb, Research Offers a Path Forward
By Brenna Callahan
A NEW REPORT FROM The Michael J. Fox Foundation puts a sharper price tag on Parkinson’ s disease and atypical parkinsonisms than ever:
$ 82.2 Billion in 2024
— blowing past projections more than a decade early. The analysis is the most comprehensive to date— capturing caregiving, productivity loss and prediagnosis expenses— and builds on a 2019 report that put Parkinson’ s estimated cost at $ 52 billion in 2017.
The takeaway is stark. Parkinson’ s isn’ t just a health crisis— it’ s a growing economic one, placing mounting pressure on individuals, families and public programs alike. And it underscores the opportunity before us— research breakthroughs can change the trajectory of this burden.
To address the rising cost of Parkinson’ s will require urgent policy action and sustained research investment to build on decades of progress in understanding and treating Parkinson’ s.
In March, as the new report was published, 300 advocates from 49 states gathered in Washington, D. C. to push for increased federal research investment— part of a broader effort by the Foundation and its partners to turn scientific momentum into real-world impact.
That momentum is real. Parkinson’ s has entered a new era of research— one focused on early detection, prevention and precision medicine— that will help curb these expanding costs.( Read more about the future of personalized medicine on page 7.)
This shift toward proactive, precision medicine could change the trajectory of the disease for millions with Parkinson’ s and those at risk— and, over time, reduce the long-term human and economic burden.